Algernon Pharmaceuticals Inc. (AGN.CN)
CAD 0.07
(0.0%)
CAD 0.07
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.78 Million CAD | -12.08% |
| 2022 | -6.05 Million CAD | 21.65% |
| 2021 | -7.72 Million CAD | 8.24% |
| 2020 | -8.41 Million CAD | -348.29% |
| 2019 | -1.87 Million CAD | -100.22% |
| 2018 | -937.59 Thousand CAD | 50.41% |
| 2017 | -1.89 Million CAD | 72.51% |
| 2016 | -6.87 Million CAD | -842.17% |
| 2015 | -729.89 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1003.90 CAD | 99.81% |
| 2024 Q1 | -521.55 Thousand CAD | 79.36% |
| 2024 Q3 | 1.44 Million CAD | 143929.58% |
| 2023 Q4 | -2.52 Million CAD | -124.11% |
| 2023 Q2 | -1.24 Million CAD | 33.64% |
| 2023 FY | -6.78 Million CAD | -12.08% |
| 2023 Q1 | -1.87 Million CAD | 15.2% |
| 2023 Q3 | -1.12 Million CAD | 9.61% |
| 2022 Q3 | -799.51 Thousand CAD | 56.42% |
| 2022 Q4 | -2.21 Million CAD | -177.2% |
| 2022 FY | -6.05 Million CAD | 21.65% |
| 2022 Q2 | -1.83 Million CAD | -52.83% |
| 2022 Q1 | -1.2 Million CAD | -399.68% |
| 2021 Q4 | -240.26 Thousand CAD | 85.65% |
| 2021 Q1 | -3.43 Million CAD | -14.95% |
| 2021 Q2 | -2.38 Million CAD | 30.55% |
| 2021 Q3 | -1.67 Million CAD | 29.82% |
| 2021 FY | -7.72 Million CAD | 8.24% |
| 2020 Q2 | -787.4 Thousand CAD | -373.38% |
| 2020 Q4 | -2.98 Million CAD | 34.97% |
| 2020 Q3 | -4.59 Million CAD | -483.44% |
| 2020 Q1 | -166.33 Thousand CAD | 60.87% |
| 2020 FY | -8.41 Million CAD | -348.29% |
| 2019 FY | -1.87 Million CAD | -100.22% |
| 2019 Q4 | -425.06 Thousand CAD | 20.09% |
| 2019 Q3 | -531.91 Thousand CAD | -19.58% |
| 2019 Q2 | -444.81 Thousand CAD | 9.92% |
| 2019 Q1 | -493.77 Thousand CAD | -158.16% |
| 2018 Q1 | -193.3 Thousand CAD | 33.77% |
| 2018 FY | -937.59 Thousand CAD | 50.41% |
| 2018 Q4 | -191.26 Thousand CAD | 51.59% |
| 2018 Q3 | -395.08 Thousand CAD | -150.15% |
| 2018 Q2 | -157.93 Thousand CAD | 18.3% |
| 2017 Q1 | -520.12 Thousand CAD | -88.27% |
| 2017 Q2 | -324.59 Thousand CAD | 37.59% |
| 2017 Q3 | -753.99 Thousand CAD | -132.29% |
| 2017 Q4 | -291.88 Thousand CAD | 61.29% |
| 2017 FY | -1.89 Million CAD | 72.51% |
| 2016 FY | -6.87 Million CAD | -842.17% |
| 2016 Q4 | -276.26 Thousand CAD | 40.91% |
| 2016 Q3 | -467.55 Thousand CAD | 76.89% |
| 2016 Q2 | -2.02 Million CAD | 50.78% |
| 2016 Q1 | -4.1 Million CAD | -681.12% |
| 2015 FY | -729.89 Thousand CAD | 0.0% |
| 2015 Q4 | -526.15 Thousand CAD | -158.25% |
| 2015 Q3 | -203.73 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asep Medical Holdings Inc | -8.22 Million CAD | 17.577% |
| BetterLife Pharma Inc. | -2.88 Million CAD | -134.722% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 11.787% |
| ChitogenX Inc. | -1.55 Million CAD | -336.371% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | -57.464% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 48.6% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -2160.392% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | -29.988% |
| Glow Lifetech Corp. | -1.64 Million CAD | -312.078% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -681.503% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -769.593% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -1895.363% |
| MYND Life Sciences Inc. | -1.51 Million CAD | -346.761% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | -453.829% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | -117.671% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | -432.08% |
| Telescope Innovations Corp. | -5.72 Million CAD | -18.402% |